Future studies will also determine whether HCC is uniquely suited for therapeutic intervention with novel TGF-β inhibitors since the Smad pathway in HCC cells is necessary for their survival rather than their growth inhibition. The gene discussed is TGFB1; the disease is hepatocellular carcinoma.